« Previous | Next » | All Messages |  GNYS Message Board Home | recommend post |  Ignore Poster

GeNOsys, Inc. Retains Alliance Advisors, LLC to Implement Investor Relations Program

PROVO, UT -- (Marketwire) -- 09/29/08 -- GeNOsys, Inc. (OTCBB: GNYS), a medical research and development company specializing in pharmaceutical, biotechnical and medical gas generating systems, today announced it has retained Alliance Advisors as the Company's investor relations representative. Alliance Advisors will immediately initiate a proactive and targeted investor relations campaign. Alan Sheinwald, of Alliance Advisors, and his team will be advising the Company in all facets of public financial communications.

Alliance Advisors is a premier information resource to institutional investors, hedge funds, independent portfolio managers, buy-side and sell-side analysts, small to large retail brokerage firms and accredited individual investors. Alliance Advisors will leverage its recognized investment community relationships to help capitalize on GeNOsys's investment opportunity. Additionally, the firm will extend GeNOsys's investor awareness programs, shareholder communications and coordinate analyst coverage for the firm.

GeNOsys, Inc. is a medical research and development company specializing in pharmaceutical, biotechnical and medial gas generating systems. The Company is currently focused on research utilizing its product line of Nitric Oxide gas generators for the potential treatment of tuberculosis and other human disease. Tuberculosis is a leading threat to global health, infecting one-third of the world's population, or approximately two billion people. Every year an additional thirty million people are infected with the bacterium and eight million people develop the active disease. With the Company's patented Nitric Oxide gas generating and delivery system and its proprietary and patented Nitric Oxide micro tablet medium manufacturing technology the Company believes that they have the potential to make a significant difference in the treatment of tuberculosis.

"GeNOsys's patented Nitric Oxide generators and proprietary and patented Nitric Oxide micro tablet is addressing not only a very large market but also a market that currently does not contain any cost-effective solutions. Tuberculosis affects billions of people worldwide, yet no new class of anti-tuberculosis drugs have been introduced in 30 years," stated Alan Sheinwald, President of Alliance Advisors. "We strongly believe that GeNOsys has positioned itself to address this market need with a strong management team, corporate strategy, and business model based on their intellectual property."

Clark Mower, Chairman of GeNOsys, commented, "The team at Alliance Advisors is well-respected and has a proven track record of representing successful companies. We are confident they will help us improve our overall communication capabilities, which includes delivering our story and subsequent milestones to a larger, targeted base of investors. We believe that the agreement with Alliance is an important step in broadening investor awareness and moving the Company forward."

About GeNOsys, Inc.

GeNOsys, Inc. (generated nitric oxide systems) is a medical research and development company specializing in pharmaceutical, biotechnical and medical gas generating systems. Nitric oxide gas is one of the medical gases that will be generated along with various combinations of beneficial medical gases suitable for the control of human disease. Distribution will be accelerated through the use of already existing distribution networks that currently sell related respiratory products. For further information, see the Company's Website at: www.genosysusa.com.

This press release may contain forward-looking statements including the Company's beliefs about its business prospects and future results of operations. These statements involve risks and uncertainties. Among the important additional factors that could cause actual results to differ materially from those forward-looking statements are risks associated with the overall economic environment, changes in anticipated earnings of the company and other factors detailed in the company's filings with the SEC. In addition, the factors underlying Company forecasts are dynamic and subject to change and therefore those forecasts speak only as of the date they are given. The Company does not undertake to update them; however, it may choose from time to time to update them and if it should do so, it will disseminate the updates to the investing public.